“…Function experiments show that ATBF1-A inhibits the enhancer of AFP and induces cell differentiation and death, while ATBF1-B promotes AFP expression by activating its enhancer ( Ninomiya et al, 2002 ; Nojiri et al, 2004 ; Jung et al, 2005 ; Sun et al, 2007 ; Cleton-Jansen et al, 2008 ; Kai et al, 2008 ). From the available studies, ATBF1 is responsible for suppressing AFP transcription by binding with its enhancer competing with hepatocyte nuclear factor-1 (HNF-1) ( Yasuda et al, 1994 ), thereby it plays an important role in cell differentiation and death ( Ishii et al, 2003 ; Jung et al, 2011 ; Perea et al, 2013 ), tumour genesis ( Sun et al, 2012 ; Sun et al, 2014 ), atrial fibrillation and embryonic development ( Benjamin et al, 2009 ; Gudbjartsson et al, 2009 ; Perea et al, 2013 ). Furthermore, ATBF1 interacts with Smads to regulate thyroid-stimulating hormone beta (TSH-β) signaling pathway ( Massagué, 2005 ; Moustakas et al, 2009 ; Massagué et al, 2012 ), thus it represses AFP expression ( Sakata et al, 2014 ).…”